| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view
|
Galvano, Fabio
|
|
2009
|
64 |
2 |
p. 431-432
|
article
|
| 2 |
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
|
Scott, Edwina N.
|
|
2009
|
64 |
2 |
p. 425-429
|
article
|
| 3 |
A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer
|
Kim, Kyoung Ha
|
|
2008
|
64 |
2 |
p. 347-353
|
article
|
| 4 |
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
|
Rubio, Joaquín Casal
|
|
2009
|
64 |
2 |
p. 379-384
|
article
|
| 5 |
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
|
Kim, Hyun Jung
|
|
2009
|
64 |
2 |
p. 371-377
|
article
|
| 6 |
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study
|
Mäenpää, Johanna
|
|
2008
|
64 |
2 |
p. 297-300
|
article
|
| 7 |
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy
|
Momiyama, Kouichi
|
|
2008
|
64 |
2 |
p. 271-277
|
article
|
| 8 |
Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus
|
Boni, Joseph
|
|
|
64 |
2 |
p. 263-270
|
article
|
| 9 |
Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus
|
Boni, Joseph
|
|
2008
|
64 |
2 |
p. 263-270
|
article
|
| 10 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
|
Waters, S. H.
|
|
2009
|
64 |
2 |
p. 407-412
|
article
|
| 11 |
Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine
|
Parker, William B.
|
|
2008
|
64 |
2 |
p. 253-261
|
article
|
| 12 |
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer
|
Lee, Gyeong-Won
|
|
2008
|
64 |
2 |
p. 385-390
|
article
|
| 13 |
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
|
Lee, Kyung Hee
|
|
2008
|
64 |
2 |
p. 317-325
|
article
|
| 14 |
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
|
Saban, Nina
|
|
2009
|
64 |
2 |
p. 213-221
|
article
|
| 15 |
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
|
Thompson, Patrick A.
|
|
2008
|
64 |
2 |
p. 243-251
|
article
|
| 16 |
In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
|
Abu Ajaj, Khalid
|
|
2009
|
64 |
2 |
p. 413-418
|
article
|
| 17 |
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
|
Schmid, Peter
|
|
2008
|
64 |
2 |
p. 401-406
|
article
|
| 18 |
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients
|
Specenier, Pol M.
|
|
2008
|
64 |
2 |
p. 233-241
|
article
|
| 19 |
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma
|
Gong, Youling
|
|
2008
|
64 |
2 |
p. 327-333
|
article
|
| 20 |
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
|
Ishida, Takanori
|
|
2008
|
64 |
2 |
p. 361-369
|
article
|
| 21 |
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
|
Mita, Monica
|
|
2008
|
64 |
2 |
p. 287-295
|
article
|
| 22 |
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
|
Kilburn, Lindsay B.
|
|
2008
|
64 |
2 |
p. 335-340
|
article
|
| 23 |
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat
|
Abraham, Premila
|
|
2008
|
64 |
2 |
p. 279-285
|
article
|
| 24 |
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
|
Lorizzo, Katia
|
|
2008
|
64 |
2 |
p. 301-306
|
article
|
| 25 |
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
|
Connolly, Kate
|
|
2008
|
64 |
2 |
p. 307-316
|
article
|
| 26 |
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
|
Tanaka, Satoru
|
|
2008
|
64 |
2 |
p. 341-346
|
article
|
| 27 |
The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells
|
Ascione, Alessandro
|
|
2009
|
64 |
2 |
p. 419-424
|
article
|
| 28 |
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
|
Tsavaris, Nicolas
|
|
2008
|
64 |
2 |
p. 391-398
|
article
|
| 29 |
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
|
Tsavaris, Nicolas
|
|
2009
|
64 |
2 |
p. 399
|
article
|
| 30 |
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
|
Kim, Jong Gwang
|
|
2008
|
64 |
2 |
p. 355-360
|
article
|
| 31 |
Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells
|
Suzuki, Maiko
|
|
2008
|
64 |
2 |
p. 223-232
|
article
|
Journal description